Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11450667 | 0.90 | OPRD1 (0.69) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15738051 | 0.90 | OPRM1 (0.69) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28136408 | 0.89 | OPRD1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16616437 | 0.89 | OPRD1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15734327 | 0.89 | OPRD1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27672335 | 0.89 | OPRM1 (0.67) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL2856631 | 0.88 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29360168 | 0.88 | OPRM1 (0.66) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL157912 | 0.87 | OPRD1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3982466 | 0.87 | OPRD1 (0.65) | OPRM1OPRD1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480624-B1 | PHARMACEUTICAL TABLET | PHARMACIA CORP (US) | 2006-11-29 | — | — | EP | claimed |
| EP-2312933-B1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | TASMANIAN ALKALOIDS PTY LTD (AU) | 2023-09-20 | — | — | EP | disclosed |
| US-10791691-B2 | Papaver somniferum with high concentration of codeine | TASMANIAN ALKALOIDS PTY. LTD. (AU) | 2020-10-06 | — | — | US | disclosed |
| EP-3506736-A1 | P. SOMNIFERUM PLANTS FOR THE PRODUCTION OF CODEINE | Tasmanian Alkaloids Pty. Ltd. (AU) | 2019-07-10 | — | — | EP | disclosed |
| US-20190185869-A1 | P. SOMNIFERUM PLANTS FOR THE PRODUCTION OF CODEINE | TASMANIAN ALKALOIDS PTY LTD (AU) | 2019-06-20 | — | — | US | disclosed |
| US-20190048017-A1 | METHOD FOR CATALYTIC PREPARATION OF HYDROMORPHONE, HYDROCODONE, AND OTHER OPIATES | CODY LABORATORIES INC (US) | 2019-02-14 | — | — | US | disclosed |
| US-10081636-B2 | Method for catalytic preparation of hydromorphone, hydrocodone, and other opiates | CODY LABORATORIES, INC. (US) | 2018-09-25 | — | — | US | disclosed |
| WO-2018039749-A1 | P. SOMNIFERUM PLANTS FOR THE PRODUCTION OF CODEINE | TASMANIAN ALKALOIDS PTY LTD (AU) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018009856-A1 | METHOD FOR CATALYTIC PREPARATION OF HYDROMORPHONE, HYDROCODONE AND OTHER OPIATES | CODY LABORATORIES, INC. (US) | 2018-01-11 | — | — | WO | disclosed |
| US-20180009821-A1 | METHOD FOR CATALYTIC PREPARATION OF HYDROMORPHONE, HYDROCODONE, AND OTHER OPIATES | LANNETT COMPANY, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20170280647-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | TASMANIAN ALKALOIDS PTY LTD (AU) | 2017-10-05 | — | — | US | disclosed |
| US-9648815-B2 | Papaver somniferum with high concentration of codeine | TASMANIAN ALKALOIDS PTY. LTD. (AU) | 2017-05-16 | — | — | US | disclosed |
| US-8541647-B2 | Papaver somniferum with high concentration of codeine | Tasmania Alkaloids Pty, Ltd. (AU) | 2013-09-24 | — | — | US | disclosed |
| US-20130205452-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | TASMANIA ALKALOIDS PTY. LTD. (AU) | 2013-08-08 | — | — | US | disclosed |
| EP-2312933-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | Tasmanian Alkaloids Pty. Ltd. (AU) | 2011-04-27 | — | — | EP | disclosed |
| US-20100234600-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | CERBERUS BUSINESS FINANCE, LLC, AS COLLATERAL AGENT | 2010-09-16 | — | — | US | disclosed |
| WO-2009143574-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | TASMANIAN ALKALOIDS PTY LIMITED (AU) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10791691-B2 | Papaver somniferum with high concentration of codeine | OPRM1, OPRK1, CPNE4 | OPRM1 1/4885OPRD1 12/4885OPRK1 2/4885 |
| US-20170280647-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | OPRM1, OPRK1, CPNE4 | OPRM1 1/4885OPRD1 12/4885OPRK1 2/4885 |
| US-20100234600-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | OPRM1, OPRK1, POF1B | OPRM1 1/4885OPRD1 5/4885OPRK1 2/4885 |
| US-20180009821-A1 | METHOD FOR CATALYTIC PREPARATION OF HYDROMORPHONE, HYDROCODONE, AND OTHER OPIATES | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20130205452-A1 | PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE | OPRM1, OPRK1, POF1B | OPRM1 1/4885OPRD1 5/4885OPRK1 2/4885 |
| US-10081636-B2 | Method for catalytic preparation of hydromorphone, hydrocodone, and other opiates | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20190048017-A1 | METHOD FOR CATALYTIC PREPARATION OF HYDROMORPHONE, HYDROCODONE, AND OTHER OPIATES | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.